Morningstar
•
Oct 28, 2026
BridgeBio Pharma, Inc.: Positive Outlook for BridgeBio Pharma's Rare-Disease Pipeline As Attruby Is Poised To Support Growth
Summary
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
CYTK: Lowering target price to $52.00
Oct 28, 2026
•
CYTK
ROIV: Raising target price to $38.00
Oct 28, 2026
•
ROIV
KRYS: Lowering target price to $353.00
Oct 28, 2026
•
KRYS
PTGX: Raising target price to $148.00
Oct 28, 2026
•
PTGX
CYTK: Raising target price to $54.00
Oct 21, 2026
•
CYTK
